#AAD2019

Highlights AEDV

In 77TH AAD Congress

1-5 March 2019

★ Washington ★

Scientific Initiative of:

Sponsored by:

NOVARTIS

#AAD2019

Highlights AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Pediatric dermatology:
Dr. Oriol Corral Magaña

Scientific Initiative of:

Sponsored by:

NOVARTIS

F028: NURSERY TALES: CHALLENGING DERMATOSES IN NEWBORN (DR. RAEGAN)



Adapted from F028. Dr. Raegan

Zhao CY, Murrell DF. Autoimmune blistering diseases in females: a review. International Journal of Women's Dermatology. 2015 Feb;1(1):4–12.

F028: NURSERY TALES: CHALLENGING DERMATOSES IN NEWBORN (DR. HUNT)

CM & Sturge Weber Syndrome

- RMI is better predictor than localization for neurologic outcomes.
- For practical reasons guidelines based on clinical phenotype are used. The best clinical predictor for adverse outcomes are forehead lesions.



PAEDIATRIC DERMATOLOGY
BJD British Journal of Dermatology

New vascular classification of port-wine stains: improving prediction of Sturge–Weber risk

R. Waelchli,[1] S.E. Aylett,[2,3] K. Robinson,[2] W.K. Chong,[4] A.E. Martinez[1] and V.A. Kinsler[1,5]

[1]Department of Paediatric Dermatology, [2]Department of Neurosciences and [4]Department of Paediatric Neuroradiology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K.
[3]Neurosciences Unit and [5]Clinical and Molecular Genetics Unit, UCL Institute of Child Health, London, U.K.

- RMI prior to 6 month have not demonstrate better outcome.
- False negative exists. Neurologist follow up is adviced.

DOI: 10.1111/pde.13304

REVIEW

WILEY Pediatric Dermatology

Screening for Sturge-Weber syndrome: A state-of-the-art review

Michaela Zallmann MBBS[1,2] | Richard J. Leventer MBBS, PhD[2,3,4] | Mark T. Mackay MBBS, PhD[2,3,4] | Michael Ditchfield MBBS, MD[5,6] | Philip S. Bekhor MBBS[7] | John C. Su MBBS, MA, MSt, MEpi, MBA[1,2,4,7]

SAVI: Sting Associated Vasculopathy with onset in Infancy (Dr. Ho)

- Systemic disease with skin vasculopathy, ILD and systemic inflamation.
- Good cutaneous response with JAK inh.

Dermatomyositis clinical pearls:

- Facial erythema can be very similar to SEL and histology can not distinguish both entities. Nasogenian involvement is not present in Lupus (Dr. Abeer).
- In Amyopathic DM only 10% of patients will respond to antimalarial alone. Combination of antimalarial or adjuvant use of other imunosuppressive treatments (MTX, MMF) may be necessary. IVIG present good outcomes (Dr. Cobos)
- Emerging therapies: Tofacitinib (JAK inh) shows promising results.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation. 2018 Jul 2;128(7):3041–52.

Kerrigan SA, McInnes IB. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes? Current Rheumatology Reports [Internet]. 2018 Dec;20(12). Available from: http://link.springer.com/10.1007/s11926-018-0792-7

Kurtzman DJB, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatology. 2016 Aug 1;152(8):944.

S025: CHALLENGING ADULT & PEDIATRIC AUTOIMMUNE CONNECTIVE TISSUE DISEASES CASES: PEARLS FOR DIAGNOSIS & MANAGEMENT

Juvenile Dermatomyositis Pearls (Dr. Vleugels):

- Not need to routinely run out malignancies, neither lung disease (important in anti-MDA5 DM in adults).
- Early and aggressive treatment must be initiate to avoid calcinosis.
- Follow up! True amyopathic disease is rare.

Crohn, infliximab and psoriasis-like dermatitis (Dr. Coughlin & Dr. Patel)

- 10,1% of patients.
- Pruritic & painful.
- Scalp > retro-auricular
- Switch to Adalimumab or Ustekinumab improve lesions.

Segmental Stiff Skin Syndrome (SSS) (Dr. Kurtzman)

- Rare. FBN-1 mutation. Typically presents in childhood.
- Mimics cutaneous systemic sclerosis. Hard skin around the pelvic or shoulder girdle.
- Without systemic involvement, but can cause joint contracture.
- No definitive treatment.
- Reported personal good experience with MMF (13º improvement in articular extension)